A randomized phase II study of a combination of docetaxel and bevacizumab versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with bevacizumab and platinum-based chemotherapy.

A randomized phase II study of a combination of docetaxel and bevacizumab versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with bevacizumab and platinum-based chemotherapy. - A randomized phase II study of a combination of docetaxel and bevacizumab versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with bevacizumab and platinum-based chemotherapy.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005214

Enrollment

120

Registered

2011-03-08

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Bevacizumab and Docetaxel Docetaxel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically or cytrologically confirmed diagnosis of NSCLC with a adeno or large cell carcinoma. Patients must have had progressive disease after Bevacizumab and platinum-based chemotherapy;consisting of minimum of one cycle of maintenance Previous treatment within 6 weeks from 3 week of study enrollment. Tumors must have measurable disease by RECIST version 1.1 20 years of age or older. ECOG performance status 0 or 1. Any major surgery within 4 weeks of study enrollment. No radiotherapy within 2 weeks of study enrollment. No problem adequate organ function.

Exclusion criteria

Exclusion criteria: Subjects with interstitial pneumonia or pulmonary fibrosis. Uncontrolled Active infection. Subjects with brain metastases. Concurrent use of steroid therapy. Uncontrolled pleural. Subjects with previous malignancies. Any other reason that,in the opinion of the investigator precludes the subject from participating in the study.

Design outcomes

Primary

Measure	Time frame
PFS	—

Countries

Japan

Contacts

Public ContactFumiyoshi.Ohyanagi

Cancer Institute Ariake Hospital of JFCR Toracic Medical Oncology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026